Komori
Changes in Officers4534Mochida Pharmaceutical Co.,Ltd.Pharmaceuticals

Notice of Personnel Changes

Effective 9 November 2026, the responsibilities and concurrent roles of 1 director and 2 executive officers will be reviewed, and the responsibilities and positions of 4 department-manager-level personnel will be changed. In addition, the Overseas Business Office will be integrated into the Licensing Department, and a new BS Business Promotion Office responsible for the biosimilar business will be established.

Worth reading
28Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Who is moving to which position

Scheduled Appointment Date9 November 2026 (orders issued on the same date)
Details of organizational changes

Integrate the Overseas Business Office into the Licensing Department within the Business Development Division. Establish the BS Business Promotion Office within the Business Promotion Division.

Who is moving to which position
ItemDetails
Scheduled Appointment Date9 November 2026 (orders issued on the same date)
Details of organizational changesIntegrate the Overseas Business Office into the Licensing Department within the Business Development Division. Establish the BS Business Promotion Office within the Business Promotion Division.
Items this document does not state (19)
Resolution dateDate of departureName of appointeeAppointee's new positionAppointee's previous positionAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeName of departing officerFormer position of departing officerNew position of departing officerReason for departureWhether the incumbent will remain in officeReason for changeReasons for appointmentNumber of directors after the changeFiling as an independent officerChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Overseas Business Office will be integrated into the Licensing Department to improve operational efficiency, while the BS Business Promotion Office will be established to strengthen the biosimilar business. No reasons were given for the individual changes in executive responsibilities or personnel assignments.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Personnel Changes | Mochida Pharmaceutical Co.,Ltd. (4534) timely disclosure | Komori